Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

Clinical trial NCT04660097 · COMPLETED

Trial details

NCT number: NCT04660097
Sponsor: Henan Cancer Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

SCLC, Extensive Stage

Start date: 2021-05-20
Primary completion: 2024-06-30
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.